All In Biotech

Drug Trial Radar · NCT07785609

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of MK-2010 in Combination With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Sep 30, 2031

Study completion Sep 30, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced may mean the cancer has spread to nearby or other parts of the body. The cancer may not be able to be treated with surgery or radiation, which uses beams of intense energy (like X-rays) to shrink or get rid of tumors. Some cancers may not have gone away or came back after previous treatment. MK-2010, the trial treatment, is designed to help the immune system fight cancer. This trial will look at MK-2010 when given with another trial treatment called sacituzumab tirumotecan (sac-TMT). Sac-TMT is an antibody-drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this trial are to learn: * About the safety of MK-2010 with sac-TMT and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems. * How many participants who receive MK-2010 with sac-TMT have the cancer respond to treatment. Respond means the cancer gets smaller or goes away.

Conditions

  • Advanced Solid Tumors
  • Malignant Neoplasm

Interventions

  • MK-2010Biological

    Administered as an intravenous (IV) infusion

  • Sacituzumab tirumotecanBiological

    Administered as an IV infusion

  • Histamine H1 Receptor AntagonistDrug

    Administered as a premedication per the approved product label

  • Histamine H2 Receptor AntagonistDrug

    Administered as a premedication per the approved product label

  • Acetaminophen (or equivalent)Drug

    Administered as a premedication per the approved product label

  • Dexamethasone (or equivalent)Drug

    Administered as a premedication per the approved product label

  • Steroid mouthwash (dexamethasone or equivalent)Drug

    Administered orally per the approved product label as a rescue medication

  • EpinephrineDrug

    Administered for emergency use per the approved product label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 27 months
  2. Number of Participants Who Experience Dose Limiting Toxicity (DLT) (Part 1 Only)Time frame: Up to approximately 28 days
  3. Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 24 months
  4. Objective Response Rate (ORR)Time frame: Up to approximately 60 months

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • START San Antonio ( Site 0220)

    San Antonio, Texas · Recruiting

  • Queen Mary Hospital ( Site 2300)

    Hong Kong, Hong Kong · Recruiting

  • Cantonal Hospital St.Gallen ( Site 1100)

    Sankt Gallen, Switzerland · Recruiting

  • Ospedale Regionale Bellinzona e Valli ( Site 1102)

    Bellinzona, Canton Ticino, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.